|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2066 USD | -1.20% |
|
-8.83% | -40.25% |
Projected Income Statement: Virax Biolabs Group Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.00856 | - | 0.00633 | 0.004 | 0.004 |
| Change | - | - | - | - | -36.81% | 0% |
| EBITDA | - | -5.733 | - | - | - | - |
| Change | - | - | - | - | - | - |
| EBIT 1 | - | -5.733 | - | -6.163 | -5.184 | -5.198 |
| Change | - | - | - | - | 15.88% | -0.27% |
| Interest Paid 1 | - | - | - | - | -0.031 | - |
| Earnings before Tax (EBT) 1 | -1.75 | -5.458 | - | -6.204 | -5.216 | -5.198 |
| Change | - | -211.9% | - | - | 15.92% | 0.35% |
| Net income 1 | -1.709 | -5.457 | -6.734 | -6.061 | -4.942 | -5.198 |
| Change | - | -219.37% | -23.38% | 9.98% | 18.47% | -5.18% |
| Announcement Date | 12/08/22 | 14/06/23 | 20/08/24 | 02/07/25 | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Virax Biolabs Group Limited
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Announcement Date | 12/08/22 | 14/06/23 | 20/08/24 | 02/07/25 | - | - |
Estimates
Cash Flow Forecast: Virax Biolabs Group Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| CAPEX 1 | - | - | - | 0.9525 | 0.6039 |
| Change | - | - | - | - | -36.6% |
| Free Cash Flow (FCF) 1 | -0.2291 | -0.5484 | -2.711 | -4.987 | -3.246 |
| Change | - | -139.34% | -394.3% | -83.95% | 34.91% |
| Announcement Date | 27/12/21 | 12/08/22 | 14/06/23 | 20/08/24 | 02/07/25 |
1USD in Million
Estimates
Forecast Financial Ratios: Virax Biolabs Group Limited
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | -66,971.5% | - | - | - | - |
| EBIT Margin (%) | - | - | - | -66,971.5% | - | -97,360.19% | -129,600% | -129,950% |
| EBT Margin (%) | - | - | - | -63,758.88% | - | -98,007.74% | -130,400% | -129,950% |
| Net margin (%) | - | - | - | -63,755.72% | - | -95,754.34% | -123,550% | -129,950% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | -1,294.67% | -2,453.52% | -72.67% | -49.9% | -64.68% | - | - |
| ROE | - | 65.75% | 172.53% | -141.63% | -95.98% | -114.47% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | -0.69x | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | 9,540.13% | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EPS 1 | - | - | - | - | -3.36 | -1.62 | -0.4 | -0.24 |
| Change | - | - | - | - | - | 51.79% | 75.31% | 40% |
| Nbr of stocks (in thousands) | - | - | - | - | 2,362 | 4,342 | 7,423 | 7,423 |
| Announcement Date | - | - | - | - | 20/08/24 | 02/07/25 | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E ratio | -0.52x | -0.86x |
| PBR | - | - |
| EV / Sales | 383x | 383x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2066USD
Average target price
1.000USD
Spread / Average Target
+384.03%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRAX Stock
- Financials Virax Biolabs Group Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition